This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
Home
Products
MenQuadfiTM▼  (meningococcal (group A,C,W,Y) conjugate vaccine)

MenQuadfiTM

meningococcal (group A,C,W,Y) conjugate vaccine

This is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.

Profile

MenQuadfiTM is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.

Before you prescribe this vaccine please refer to the SmPC.17

Evidence

Why help protect your patients with MenQuadfiTM?

Invasive meningococcal disease (IMD) is associated with a significant risk of death and severe sequelae. 50% of IMD cases are fatal if left untreated and even when the disease is diagnosed and treated early, 8-15% IMD patients will die. Sequelae such as neurological and hearing impairment or amputation occur in up to 20% of survivors.1,2

IMD remains a serious threat in the UK and abroad. In the meningitis belt of sub Saharan Africa, seasonal hyperendemicity is observed every dry season with weekly incidence rates rising to up to 10/100,000 population.3,4 IMD epidemics have also been linked to Islamic pilgrimages to Makkah, resulting in importations of IMD to the UK.5 Globally, specific serogroups can shift unpredictably within regions over time.6-8

Usage

MenQuadfi is designed to help protect individuals aged 12 months and older against IMD caused by serogroups A, C, W and Y. It is the only MenACWY conjugate vaccine in Europe available in a fully liquid formulation.9,10 This can potentially save time and reduce reconstitution errors.11

MenQuadfi uses a tetanus toxoid carrier protein, which is able to impact the T-cell dependent immune system.12

In clinical trials, the safety of MenQuadfi was shown to be similar to comparator vaccines.13-16

A MenACWY certificate will be provided on ordering MenQuadfi.

Presentation

1 single dose vial (0.5mL)

Schedule

1 dose

Further dose

A single 0.5mL dose may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.

Age range

12 months +
Ways to Order 

You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre. Read more about ordering vaccines.

CALL 0800 854 430

References
  1. WHO. Meningococcal meningitis. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/meningococcal-meningitis. Updated 19 April 2018 (Accessed April 2024).
  2. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Last updated 2019. Accessible from: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet (Accessed April 2024).
  3. W. Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483-498. doi:10.1016/j.jinf.2020.05.079.
  4. TravelHeallthPro. Meningococcal Disease. 2020. Accessible from: https://travelhealthpro.org.uk/factsheet/42/meningococcal-disease (Accessed April 2024).
  5. Public Health England. Green Book Chapter 22: Meningococcal. 2016 (Accessed April 2024).
  6. Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY TT Vaccine: A Review. Infect Dis Ther. 2019;8(3):307-333.
  7. National Reference Laboratory. National Institute of Public Health. Czech Republic. Czech Republic epidemiology data table. http://www.szu.cz/tema/prevence/meningokokove infekce. Reports: 2019, 2018, 2017, 2016, 2015, 2014.
  8. Institut Pasteur, Bilan IIM 2017 2018 2099 Santé Publique France, Rapport ECDC Invasive Meningococcal Disease, Recontres Pédiatriques 2020. France epidemiology data table.
  9. MenveoTM Summary of Product Characteristics.
  10. NimenrixTM Summary of Product Characteristics.
  11. DeCoster I, Fournie X, Faure C, et al. Assessment of preparation time with fully liquid versus on fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;(33):3976-3982.
  12. Bröker M, Berti F, Costantino P. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum Vaccin Immunother. 2016;12(7):1808-1824.
  13. van der Vliet D, Vesikari T, Sandner B, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50.
  14. Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560-3569.
  15. Data on file. MET43 Safety.
  16. Esteves Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study. Vaccine. 2020;38(28):4405-4411.
  17. MenQuadfiTM Summary of Product Characteristics

MAT-XU-2400154 (v2.0) Date of preparation: April 2024